menu
Milestones
2001
April
SinoMab was incorporated in Hong Kong
2019
June
SinoMab was recognized as a “Principal Leading Project of the 13th Suzhou Industrial Park Science and Technology Leading Talents Appraisal” (蘇州工業園區第十三屆科技領軍人才重大領軍項目).
November
Successfully listed on HKSE, became the first Hong Kong-based biopharmaceutical company listed on the Main Board
2020
January
Granted “Most Popular Newly Listed Company Award” at the “4th Hong Kong Golden Stocks Awards”
2021
May
Granted “Most Outstanding Biopharmaceutical Company of the Year” at the “Hong Kong’s Most Outstanding Business Awards” organized by CorpHub
2022
January
Awarded “Best Small and Mid-Cap Company” at the “6th Hong Kong Golden Stock Awards Ceremony” and the “Listed Company with Most Growth Potential” in the selection of “2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies”.
July
SinoMab received the highest subsidy from HKSTP for the clinical study of SN1011 for the treatment of multiple sclerosis (MS)
2023
April
Flagship Product SM03 (Suciraslimab) achieved primary endpoint in Phase III Clinical Trial for Rheumatoid Arthritis in China
September
BLA accepted by the NMPA for SM03 (Suciraslimab) in the treatment of Rheumatoid Arthritis
December
Awarded “The Best Small and Medium Sized Company” at the “8th Zhitong Caijing Listed Companies Awards”
2024
January
SinoMab received HKD6.5 million subsidy from HKSTP for the clinical study of SM17 for the treatment of atopic dermatitis (AD)
